AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is scheduled to be releasing its earnings data before the market opens on Monday, October 30th. Analysts expect AcelRx Pharmaceuticals to post earnings of ($0.28) per share for the quarter.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). The firm had revenue of $2.66 million for the quarter, compared to the consensus estimate of $2.63 million. On average, analysts expect AcelRx Pharmaceuticals to post $-1.12 EPS for the current fiscal year and $-0.94 EPS for the next fiscal year.
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) opened at 1.85 on Friday. The firm’s market cap is $83.95 million. The stock has a 50 day moving average of $3.47 and a 200 day moving average of $2.90. AcelRx Pharmaceuticals, Inc. has a 52 week low of $1.55 and a 52 week high of $5.75.
WARNING: “AcelRx Pharmaceuticals, Inc. (ACRX) Scheduled to Post Earnings on Monday” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/28/acelrx-pharmaceuticals-inc-acrx-scheduled-to-post-earnings-on-monday.html.
In other AcelRx Pharmaceuticals news, CEO Vincent J. Angotti acquired 15,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $3.00 per share, with a total value of $45,000.00. Following the completion of the purchase, the chief executive officer now directly owns 15,000 shares of the company’s stock, valued at approximately $45,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the sale, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The disclosure for this sale can be found here. Insiders purchased 37,000 shares of company stock worth $112,280 over the last ninety days. 28.10% of the stock is currently owned by insiders.
Several analysts have recently issued reports on the company. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. Royal Bank Of Canada set a $6.00 target price on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. Stifel Nicolaus raised AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday. Finally, ValuEngine raised AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. AcelRx Pharmaceuticals has an average rating of “Hold” and an average target price of $6.83.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.